Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 4/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 4/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL387330 | 0.99 | PARP15 (0.47) | PARP15PARP10CA1CA2CA9 | |
| SCHEMBL14480739 | 0.97 | PARP15 (0.46) | PARP15PARP10CA1CA2CA9 | |
| SCHEMBL21509219 | 0.94 | CA1 (0.48) | PARP15PARP10CA1CA2CA9 | |
| SCHEMBL16622998 | 0.87 | TDP1 (0.57) | CA1CA2CA9LPLLIPG | |
| SCHEMBL4664263 | 0.86 | CXCR1 (0.46) | CA1CA2CA9 | |
| SCHEMBL16572193 | 0.85 | CA1 (0.46) | CA1CA2CA9HIF1ALPL | |
| SCHEMBL24658454 | 0.84 | APP (0.52) | CA1CA2CA9HIF1ALPL | |
| SCHEMBL22820134 | 0.83 | LPL (0.43) | PARP15PARP10CA1CA2CA9 | |
| SCHEMBL20911827 | 0.83 | CA1 (0.43) | CA1CA2CA9HIF1ALPL | |
| SCHEMBL2013400 | 0.83 | HIF1A (0.36) | PARP15PARP10CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | PARP15 4007/4885PARP10 3973/4885CA1 1264/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | PARP15 4007/4885PARP10 3973/4885CA1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.